


Reference Data

(Consolidated Financial Results for Q2 FY2012)



Daiichi-Sankyo

October 31, 2012

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Management / Financial Indicators	P8
8.	Capital Expenditure and Depreciation Expenses	P8
9.	Consolidated Balance Sheets	P9
10.	Consolidated Statements of Cash Flow	P11
11.	Summary of Product Outlines	P12
12.	Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			Q2 YTD					FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to forecast	to sales	Forecast	YoY	YoY
Net sales	100%	242.6	+4.7%	100%	241.6	+7.7%							100%	484.2	28.1	+6.2%	49%	100%	980.0	41.3	+4.4%
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%							30%	143.8	15.0	+11.6%	48%	31%	302.0	33.4	+12.4%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%							70%	340.4	13.2	+4.0%	50%	69%	678.0	7.9	+1.2%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%							59%	283.3	18.3	+6.9%	49%	59%	578.0	6.1	+1.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%							18%	87.2	3.2	+3.8%	46%	19%	188.0	2.9	+1.6%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%							9%	44.3	-0.1	-0.3%			not disclosed		
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%							14%	68.9	-1.6	-2.3%			not disclosed		
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%							17%	82.9	16.8	+25.5%			not disclosed		
Operating Income	13%	32.5	-25.2%	10%	24.6	+31.2%							12%	57.1	-5.1	-8.2%	57%	10%	100.0	1.8	+1.8%
Non-operating income / expenses		8.3			-15.5									-7.2	-11.4				0.0	22.0	
Non-operating income		10.3			-5.3									5.0	-4.3				not disclosed		
Non-operating expenses		2.0			10.2									12.2	7.1				not disclosed		
Ordinary Income	17%	40.8	-9.0%	4%	9.0	-58.0%							10%	49.9	-16.5	-24.8%	50%	10%	100.0	23.8	+31.2%
Extraordinary income / losses		0.6			-5.2									-4.7	-0.4				-5.0	37.3	
Extraordinary income		2.0			0.5									2.5	0.5				not disclosed		
Extraordinary losses		1.5			5.7									7.2	0.9				not disclosed		
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%							9%	45.2	-16.8	-27.2%	48%	10%	95.0	61.1	+180.1%
Income taxes / minority interests		21.0			-0.1									20.8	-4.2				45.0	21.5	
Income taxes		16.8			3.0									19.8	-2.9				not disclosed		
Minority interests		4.2			-3.1									1.1	-1.2				not disclosed		
Net Income	8%	20.4	-19.4%	2%	4.0	-66.3%							5%	24.4	-12.7	-34.3%	49%	5%	50.0	39.6	+381.6%
Effective tax rate		41%			78%									44%							
Overseas sales ratio results		54%			48%									51%							

Notes to FY2012 Q2 Results Year-on-Year Comparisons

Net Sales	Ranbaxy +28.6, Memary +6.9, Prasugrel alliance revenue +2.0, Nexium +1.8, Ranmark +1.7 Mevalotin -4.1, Plexxikon -3.3, Levofloxacin export, royalty, etc -3.2, Olmesartan -3.0, Luitpold -3.0 (appreciation of JPY to USD and EUR -4.0, appreciation of JPY to INR -20.0)
SG&A expenses	R&D: Forex impact (appreciation of JPY to USD, EUR, and INR) -1.0 Other: Forex impact (appreciation of JPY to USD, EUR, and INR) -11.0, Cost increase from new product launches
Non-operating items	"Forex gains" and "gain on valuation of derivatives" of Ranbaxy
Extraordinary losses	Loss on impairment of long-lived assets +3.5

2. Currency Rate

	Q1	Q2 YTD		Q3 YTD	Q4 YTD	Q2 YTD		FY2012
	Results	Results	YoY	Results	Results	Results	YoY	Forecast
USD/JPY (average)	80.21	79.42	-0.39			79.42	-0.39	80.00
EUR/JPY (average)	102.91	100.64	-13.14			100.64	-13.14	100.00
INR/JPY (average)	1.59	1.54	-0.29			1.54	-0.29	-

Appreciation of JPY to USD, EUR, and INR negatively affected the FY2012 Q2 results by 24 bil yen in net sales and 4.0 bil yen in operating income.
Annual impact of one yen change is estimated to affect the group's FY2012 performance by; USD: net sales 2 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income minor

3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%								377.4	-0.4	-0.1%
Inter-segment sales		0.3			0.3									0.6	0.5	
Net sales	100%	183.8	-4.2%	100%	194.2	+4.4%							100%	378.0	0.1	+0.0%
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%							28%	104.0	14.6	+16.3%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%							72%	274.1	-14.5	-5.0%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%							62%	233.6	3.4	+1.5%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%							22%	83.5	3.4	+4.3%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%							40%	150.2	-0.1	-0.0%
Operating Income	11%	20.1	-49.3%	10%	20.3	+8.9%							11%	40.4	-17.9	-30.7%
Non-operating income		2.1			1.0									3.1	-2.4	
Non-operating expenses		1.0			1.6									2.6	-0.6	
Ordinary Income	11%	21.1	-49.2%	10%	19.8	+4.2%							11%	40.9	-19.7	-32.5%
Extraordinary income		2.0			0.4									2.4	0.6	
Extraordinary losses		1.3			5.7									7.0	0.9	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%							10%	36.3	-20.0	-35.5%
Income taxes		8.1			4.4									12.5	-11.3	
Minority interests		-0.1			-0.0									-0.1	0.9	
Net Income	7%	13.7	-40.1%	5%	10.2	-4.6%							6%	23.9	-9.6	-28.8%

Ranbaxy Group	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		59.1	+48.7%		47.6	+24.0%								106.8	28.6	+36.5%
Inter-segment sales		0.7			0.3									1.0	0.5	
Net sales	100%	59.8	+49.5%	100%	47.9	+24.1%							100%	107.7	29.1	+37.0%
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%							38%	40.9	1.5	+3.7%
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%							62%	66.8	27.7	+70.7%
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%							44%	47.4	15.2	+47.1%
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%							4%	4.1	-0.5	-11.5%
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%							40%	43.2	15.7	+57.1%
Operating Income	23%	13.8	+161.9%	12%	5.6	+238.2%							18%	19.4	12.5	+180.1%
Non-operating income		8.3			-6.2									2.0	-2.8	
Non-operating expenses		0.8			8.6									9.4	7.6	
Ordinary Income	36%	21.2	+269.3%	-19%	-9.2	-317.5%							11%	12.0	2.0	+20.4%
Extraordinary income		0.0			0.0									0.1	0.0	
Extraordinary losses		0.1			-0.0									0.1	-0.0	
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%							11%	11.9	2.1	+20.7%
Income taxes		6.1			-2.3									3.8	4.3	
Minority interests		0.0			0.0									0.0	-0.0	
Net Income	25%	15.0	+118.9%	-14%	-6.9	-297.1%							8%	8.1	-2.2	-21.4%

Inter-segment Transactions	Q1			Q2			Q3			Q4			Q2 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales		-1.0			-0.6									-1.6		
Cost of sales		-0.7			-0.4									-1.1		
Gross Profit		-0.3			-0.2									-0.5		
SG&A expenses		1.1			1.2									2.3		
R&D expenses		-0.3			-0.1									-0.4		
Other expenses		1.4			1.3									2.6		
Operating Income		-1.4			-1.4									-2.8		
Non-operating income		-0.0			-0.1									-0.1		
Non-operating expenses		0.1			0.0									0.1		
Ordinary Income		-1.5			-1.5									-3.0		
Extraordinary income		-			0.0									0.0		
Extraordinary losses		0.0			-0.0									0.0		
Income before income taxes and minority interests		-1.5			-1.5									-3.0		
Income taxes		2.6			0.9									3.5		
Minority interests		4.2			-3.1									1.1		
Net Income		-8.3			0.7									-7.6		

4. Sales by Business Units

	FY2012		Q1			Q2			Q3			Q4			Q2 YTD				
	Plan *1	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																			
Consolidated Net Sales	980.0	+4.4%	242.6	+4.7%	25%	241.6	+7.7%	25%							484.2	28.1	+6.2%	49%	
Japan Company (domestic sales)	450.0	+9.8%	98.2	-2.2%	22%	106.9	+6.3%	24%							205.0	4.1	+2.0%	46%	
Olmotec	81.0	+0.1%	18.2	-10.8%	23%	19.3	-5.5%	24%							37.6	-3.3	-8.1%	46%	
Rezaltas	19.0	+41.2%	4.0	+38.6%	21%	4.1	+30.6%	22%							8.1	2.1	+34.4%	43%	
Calblock	13.0	+5.0%	2.7	-14.0%	21%	2.8	-12.9%	21%							5.5	-0.9	-13.4%	43%	
Loxonin	62.0	+1.6%	14.1	-2.0%	23%	15.6	-0.4%	25%							29.7	-0.4	-1.2%	48%	
Cravit	37.0	+1.8%	8.1	-4.2%	22%	8.4	+0.0%	23%							16.5	-0.4	-2.1%	45%	
Nexium	29.0	+642.5%	1.7	-	6%	2.7	+7.1%	10%							4.4	1.8	+71.6%	15%	
Memary	26.0	+164.3%	5.1	+128.7%	20%	5.6	+247.5%	22%							10.8	6.9	+178.6%	41%	
Mevalotin	26.0	-21.4%	6.5	-25.7%	25%	6.8	-21.8%	26%							13.3	-4.1	-23.7%	51%	
Artist	21.0	-14.4%	5.6	-8.9%	27%	5.6	-9.3%	27%							11.2	-1.1	-9.1%	54%	
Omnipaque	18.0	-23.5%	4.9	-13.2%	27%	5.3	-15.9%	29%							10.2	-1.7	-14.6%	57%	
Urief	11.0	+0.1%	2.7	+0.5%	24%	2.8	+0.1%	25%							5.4	0.0	+0.3%	50%	
Inavir	10.0	-6.8%	0.4	+10.3%	4%	0.1	-164.9%	1%							0.5	0.2	+64.7%	5%	
Ranmark	5.0	-	0.6	-	12%	1.1	-	22%							1.7	1.7	-	34%	
Vaccines	not disclosed	-	5.2	+13.9%	-	8.1	+52.5%	-							13.3	3.4	+34.6%	-	
Daiichi Sankyo Espha products	not disclosed	-	2.8	+16.2%	-	2.7	+12.7%	-							5.5	0.7	+14.5%	-	
Daiichi Sankyo Healthcare (OTC)	48.0	+4.6%	10.2	+5.0%	21%	12.8	+1.1%	27%							23.0	0.6	+2.8%	48%	
Daiichi Sankyo, Inc. (US)	115.0	-9.5%	35.9	+3.7%	31%	32.6	+10.0%	28%							68.6	4.2	+6.6%	60%	
Olmesartan	71.0	-19.2%	23.9	-3.8%	34%	21.7	+6.3%	31%							45.6	0.3	+0.7%	64%	
Benicar/Benicar HCT	54.0	-24.2%	18.9	-6.3%	35%	16.7	-0.6%	31%							35.6	-1.4	-3.7%	66%	
Azor	11.0	-8.6%	3.5	-1.7%	32%	3.5	+40.0%	32%							7.0	0.9	+15.4%	63%	
Tribenzor	6.0	+30.0%	1.6	+30.8%	26%	1.5	+34.3%	25%							3.1	0.8	+32.5%	51%	
Welchol	31.0	+15.4%	8.3	+17.5%	27%	7.2	+10.5%	23%							15.5	1.9	+14.1%	50%	
Effient (alliance revenue)	not disclosed	-	2.4	+51.8%	-	2.3	+36.4%	-							4.8	1.4	+43.8%	-	
Luitpold Pharmaceuticals, Inc. (US)	44.0	-1.7%	11.3	-10.9%	26%	7.7	-17.4%	18%							19.1	-3.0	-13.6%	43%	
Venofer	23.0	-7.4%	6.8	-7.4%	30%	3.8	-30.4%	17%							10.7	-2.2	-17.2%	46%	
Daiichi Sankyo Europe GmbH	65.0	-7.4%	13.9	-17.6%	21%	15.1	-10.8%	23%							29.0	-4.8	-14.2%	45%	
Olmesartan	48.0	-5.9%	9.9	-16.6%	21%	11.3	-6.6%	24%							21.2	-2.8	-11.6%	44%	
Olmotec/Olmotec Plus	34.0	-7.2%	6.4	-26.5%	19%	8.1	-7.6%	24%							14.5	-3.0	-17.0%	43%	
Sevikar	10.0	-8.9%	2.5	+4.5%	25%	2.3	-12.2%	23%							4.8	-0.2	-4.2%	48%	
Sevikar HCT	4.0	+18.3%	1.0	+31.6%	24%	0.9	+25.7%	23%							1.9	0.4	+28.7%	47%	
Efient (alliance revenue)	not disclosed	-	0.9	+54.7%	-	0.9	+40.5%	-							1.8	-	+47.2%	-	

	FY2012		Q1			Q2			Q3			Q4			Q2 YTD			
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
Asia, South and Central America (ASCA)^{*1}	38.0	+27.8%	7.1	+9.8%	19%	8.1	+10.1%	21%							15.1	1.4	+9.9%	40%
Daiichi Sankyo China ^{*2}	not disclosed	-	2.7	+0.9%	-	3.0	+16.0%	-							5.7	2.3	+8.4%	-
Daiichi Sankyo Taiwan	not disclosed	-	0.8	-5.9%	-	0.8	-1.3%	-							1.6	-0.1	-3.7%	-
Daiichi Sankyo Korea	not disclosed	-	1.2	+2.1%	-	1.2	+5.5%	-							2.5	0.1	+3.7%	-
Daiichi Sankyo (Thailand)	not disclosed	-	0.3	+3.7%	-	0.3	+2.7%	-							0.6	0.0	+3.2%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	-	1.2	+14.2%	-	1.2	-22.5%	-							2.4	-0.2	-7.3%	-
Daiichi Sankyo Venezuela	not disclosed	-	0.8	+87.0%	-	1.4	+49.5%	-							2.3	0.9	+61.5%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	-	0.1	-	-	0.1	-	-							0.2	0.2	-	-
Ranbaxy Laboratories Limited	179.0	+2.0%	59.1	+48.7%	33%	47.6	+24.0%	27%							106.8	28.6	+36.5%	60%
Others	41.0	+14.7%	6.8	-38.0%	17%	10.7	+13.1%	26%							17.6	-3.0	-14.4%	43%
Levofloxacin export, royalty, etc	3.0	-63.2%	1.2	-60.1%	41%	1.0	-56.6%	34%							2.3	-3.2	-58.6%	75%
Plexikon	not disclosed	-	0.1	-96.1%	-	1.4	-24.6%	-							1.5	-3.3	-68.4%	-

Currency rates for overseas subsidiaries

	Plan	Q1 Results	Q2 YTD Results	Q3 YTD results	Q4 YTD Results	Q2 YTD Results
USD/JPY (average)	80.00	80.21	79.42			79.42
EUR/JPY (average)	100.00	102.91	100.64			100.64
INR/JPY (average)	-	1.59	1.54			1.54

New Product Launches

Apr 2012: Ranmark (anti-RANKL antibody for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors) launched in Japan.

Sep 2012: Tenelia (DPP-4 inhibitor for the treatment of type 2 diabetes mellitus) launched in Japan. □

Notes

*1 Since companies in China, Brazil, Venezuela and Mexico will change their fiscal year-ends from December to March, their FY2012 financial results will be for 15 months.

*2 Daiichi Sankyo Pharmaceutical (Beijing) and Daiichi Sankyo Pharmaceutical (Shanghai) are consolidated as Daiichi Sankyo China.

[Reference] Sales in Local Currency

	FY2012		Q1			Q2			Q3			Q4			Q2 YTD			
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																		
Daiichi Sankyo, Inc. (US)	1,438	-10.6%	448	+5.7%	31%	415	+8.7%	29%							863	57	+7.1%	60%
Olmesartan	888	-20.2%	298	-2.0%	34%	276	+4.9%	31%							574	7	+1.2%	65%
Benicar/Benicar HCT	675	-25.1%	235	-4.5%	35%	213	-1.8%	32%							448	-15	-3.2%	66%
Azor	138	-9.6%	44	+0.2%	32%	44	+37.4%	32%						88	12	+16.0%	64%	
Tribenzor	75	+28.5%	19	+33.3%	26%	19	+33.0%	26%						39	10	+33.2%	51%	
Welchol	388	+14.1%	103	+19.7%	27%	92	+9.5%	24%						195	25	+14.7%	50%	
Effient (alliance revenue)	not disclosed	-	30	+54.7%	-	30	+35.4%	-						60	18	+44.5%	-	
USD Mn																		
Luitpold Pharmaceuticals, Inc. (US)	550	-2.8%	141	-9.2%	26%	98	-18.5%	18%							240	-37	-13.2%	44%
Venofer	288	-8.5%	85	-5.6%	30%	49	-31.0%	17%						134	-27	-16.8%	47%	
EUR Mn																		
Daiichi Sankyo Europe GmbH	650	+0.9%	135	-6.0%	21%	153	-0.2%	24%							288	-9	-3.0%	44%
Olmesartan	480	+2.5%	96	-4.8%	20%	115	+4.4%	24%						211	0	+0.0%	44%	
Olmetec/Olmetec Plus	340	+1.1%	62	-16.2%	18%	82	+3.1%	24%						145	-10	-6.2%	43%	
Sevikar	100	-0.7%	24	+19.3%	25%	23	-1.1%	24%						48	4	+8.3%	48%	
Sevikar HCT	40	+28.9%	9	+50.1%	24%	9	+41.0%	23%						19	6	+45.5%	47%	
Effient (alliance revenue)	not disclosed	-	9	+76.5%	-	9	+57.9%	-						18	7	+66.5%	-	
INR Bn																		
Ranbaxy Laboratories Limited	105	+3.8%	37	+71.1%	35%	32	+53.1%	31%							69	27	+62.2%	66%

5. Sales of Global Products

	FY2012		Q1			Q2			Q3			Q4			Q2 YTD				
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																			
Olmесartan	237.0	-5.1%	60.0	-5.3%	25%	60.8	+0.6%	26%							120.8	-3.0	-2.4%	51%	
Olmесtec (JPN)	81.0	+0.1%	18.2	-10.8%	23%	19.3	-5.5%	24%							37.6	-3.3	-8.1%	46%	
Rezaltas (JPN)	19.0	+41.2%	4.0	+38.6%	21%	4.1	+30.6%	22%							8.1	2.1	+34.4%	43%	
Benicar/Benicar HCT (US)	54.0	-24.2%	18.9	-6.3%	35%	16.7	-0.6%	31%							35.6	-1.4	-3.7%	66%	
Azor (US)	11.0	-8.6%	3.5	-1.7%	32%	3.5	+40.0%	32%							7.0	0.9	+15.4%	63%	
Tribenzor (US)	6.0	+30.0%	1.6	+30.8%	26%	1.5	+34.3%	25%							3.1	0.8	+32.5%	51%	
Olmесtec/Olmесtec Plus (EU)	34.0	-7.2%	6.4	-26.5%	19%	8.1	-7.6%	24%							14.5	-3.0	-17.0%	43%	
Sevikar (EU)	10.0	-8.9%	2.5	+4.5%	25%	2.3	-12.2%	23%							4.8	-0.2	-4.2%	48%	
Sevikar HCT (EU)	4.0	+18.3%	1.0	+31.6%	24%	0.9	+25.7%	23%							1.9	0.4	+28.7%	47%	
Other subsidiaries, export, etc	18.0	+9.2%	4.0	+20.6%	22%	4.3	+0.1%	24%							8.3	0.7	+9.1%	46%	
Prasugrel	not disclosed	-	3.3	+52.6%	-	3.2	+37.5%	-							6.5	2.0	+44.7%	-	
Effient alliance revenue (US)	not disclosed	-	2.4	+51.8%	-	2.3	+36.4%	-							4.8	1.4	+43.8%	-	
Effient alliance revenue (EU)	not disclosed	-	0.9	+54.7%	-	0.9	+40.5%	-							1.8	0.6	+47.2%	-	

6. Number of Employees

	Mar 2012 Results	Jun 2012 Results	Sep 2012 Results	Dec 2012 Results	Mar 2013 Results
<u>Total Number of Employees</u>	<u>31,929</u>	<u>32,522</u>	<u>32,563</u>		
Japan	9,308	9,435	9,338		
* Overseas	22,621	23,087	23,225		
Daiichi Sankyo Group	17,877	18,043	18,042		
* Ranbaxy Group	14,052	14,479	14,521		

* For overseas subsidiaries with different fiscal year-ends, numbers as of June-end are shown in the Sep-end columns

7. Management / Financial Indicators

	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Results	FY2012 Q2 YTD Results	FY2012 Forecast
Management Indicators					
Earnings per share (EPS)	99.6 Yen	52.6 Yen	14.8 Yen	34.6 Yen	71.0 Yen
Dividend per share	60.0 Yen	30.0 Yen	60.0 Yen	30.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	60.2 %	57.0 %	406.8 %	86.7 %	84.5 %
Dividend payment	42 JPY Bn	21 JPY Bn	42 JPY Bn	21 JPY Bn	
Return on equity (ROE)	8.2 %	- %	1.3 %	- %	
Dividend on equity (DOE)	5.0 %	- %	5.1 %	- %	
Book value per share (BPS)	1,206.1 Yen	1,196.1 Yen	1,143.5 Yen	1,126.4 Yen	
Equity ratio	57.4 %	57.2 %	53.0 %	53.0 %	
Number of treasury stock purchased	-	-	-	-	
Treasury stock purchase	- JPY Bn	- JPY Bn	- JPY Bn	- JPY Bn	
Total number of common shares	704 million	704 million	704 million	704 million	
Share price at end of period	1,606 Yen	1,620 Yen	1,508 Yen	1,290 Yen	
Market value	1,130.4 JPY Bn	1,140.3 JPY Bn	1,069.2 JPY Bn	908.1 JPY Bn	
Financial Indicators					
Total assets	1,480.2 JPY Bn	1,472.2 JPY Bn	1,518.5 JPY Bn	1,495.0 JPY Bn	
Current assets	894.1 JPY Bn	788.0 JPY Bn	861.5 JPY Bn	845.1 JPY Bn	
*1 Liquidity on hand	426.8 JPY Bn	299.7 JPY Bn	324.3 JPY Bn	314.4 JPY Bn	
Debt with interest	299.4 JPY Bn	260.7 JPY Bn	275.9 JPY Bn	270.5 JPY Bn	
Net Cash	127.4 JPY Bn	39.0 JPY Bn	48.4 JPY Bn	43.9 JPY Bn	
Equity capital	849.0 JPY Bn	842.0 JPY Bn	804.9 JPY Bn	792.9 JPY Bn	
Cash flow from operating activities	141.1 JPY Bn	46.0 JPY Bn	92.6 JPY Bn	56.5 JPY Bn	
Cash flow from investing activities	-63.0 JPY Bn	-84.8 JPY Bn	-125.1 JPY Bn	-102.0 JPY Bn	
Cash flow from financial activities	-26.0 JPY Bn	-50.3 JPY Bn	-50.2 JPY Bn	-26.0 JPY Bn	
*2 Free cash flow	78.2 JPY Bn	-38.8 JPY Bn	-32.5 JPY Bn	-45.6 JPY Bn	
Cash and cash equivalents, end of period	302.4 JPY Bn	205.1 JPY Bn	212.7 JPY Bn	137.7 JPY Bn	
Others					
Number of consolidated subsidiaries	101	102	103	105	

*1 Current deposits + marketable securities + investment securities, etc

*2 Cash flow from operating activities and investing activities

8. Capital Expenditure and Depreciation and Amortization Expenses

	FY2010 Results	FY2011 Q2 YTD Results	FY2011 Results	FY2012 Q2 YTD Results	FY2012 Plan
Capital expenditure	37.3 JPY Bn	20.4 JPY Bn	62.9 JPY Bn	31.5 JPY Bn	55.0 JPY Bn
Depreciation and amortization expense	43.9 JPY Bn	21.8 JPY Bn	46.3 JPY Bn	20.2 JPY Bn	42.0 JPY Bn
Tangible assets	27.5 JPY Bn	13.6 JPY Bn	29.4 JPY Bn	12.3 JPY Bn	
Intangible assets	16.5 JPY Bn	8.2 JPY Bn	16.8 JPY Bn	7.9 JPY Bn	

9. Consolidated Balance Sheets

(Billions of yen)

	Mar 2012	Sep 2012	YoY	Notes
ASSETS				
Current assets				
Cash and time deposits	128.9	145.9	17.0	PBT +45.2 Bn, Depreciation +20.2 Bn Decrease in accounts payable and accrued expenses -22.3 Bn, Income taxes paid -18.2 Bn Net purchase and acquisitions of proceeds from sales of non-current assets -40.3 Bn Dividend paid -21.1 Bn
Trade notes and accounts receivable	228.5	218.0	-10.5	
Marketable securities	191.3	165.4	-26.0	
Merchandise and finished goods	109.3	111.3	2.0	
Work in process	24.5	22.7	-1.8	
Raw materials and supplies	35.8	35.2	-0.6	
Deferred tax assets	94.0	92.9	-1.1	
Other current assets	51.3	55.8	4.6	
Allowance for doubtful accounts	-2.2	-2.2	0.0	
Total current assets	861.5	845.1	-16.4	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	129.3	135.2	5.9	
Machinery, equipment and vehicles, net	48.1	50.2	2.2	
Land	35.7	34.7	-0.9	
Construction in progress	33.7	39.3	5.6	
Other, net	14.5	15.8	1.3	
Total property, plant and equipment	261.2	275.2	14.0	Newly added: Kitasato Daiichi Sankyo Vaccine (KDSV) +10.5 Bn, Daiichi Sankyo +8.3 Bn
Intangible assets				
Goodwill, net	82.7	75.6	-7.1	
Other intangible assets, net	150.5	135.8	-14.8	
Total intangible assets	233.3	211.4	-21.9	
Investments and other assets				
Investment securities	104.6	105.5	1.0	
Deferred tax assets	43.2	43.3	0.1	
Other	15.0	14.8	-0.2	
Allowance for doubtful accounts	-0.3	-0.3	0.0	
Total investments and other assets	162.4	163.2	0.8	
Total non-current assets	656.9	649.9	-7.1	
Total assets	1,518.5	1,495.0	-23.5	

(Billions of yen)

	Mar 2012	Sep 2012	YoY	Notes
LIABILITIES				
Current liabilities				
Trade notes and accounts payable	61.8	75.3	13.5	
Short-term bank loans	71.1	66.5	-4.6	
Income taxes payable	5.3	5.3	0.0	
Allowance for sales returns	0.6	1.1	0.5	
Allowance for sales rebates	2.9	3.4	0.5	
Provision for loss on disaster	0.8	0.1	-0.7	
Provision for settlement expenses	39.1	39.0	-0.2	
Other current liabilities	213.3	197.3	-16.0	
Total current liabilities	395.0	387.9	-7.0	
Long-term liabilities				
Bonds payable	100.0	100.0	0.0	
Long-term debt	104.0	103.3	-0.7	
Deferred tax liabilities	52.1	49.4	-2.7	
Accrued employees' severance and retirement benefits	10.1	11.5	1.5	
Accrued directors' severance and retirement benefits	0.2	0.2	0.0	
Provision for environment measures	1.2	0.0	-1.2	
Other long-term liabilities	23.2	20.5	-2.7	
Total long-term liabilities	290.8	284.9	-5.9	
Total liabilities	685.7	672.8	-12.9	
NET ASSETS				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	742.4	745.6	3.2	Net income +24.4 Bn, Dividend paid -21.1 Bn
Treasury stock, at cost	-14.6	-14.5	0.1	
Total shareholders' equity	883.0	886.3	3.3	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	22.3	22.7	0.4	
Deferred gains or losses on hedges	0.2	0.6	0.4	
Foreign currency translation adjustments	-100.6	-116.6	-16.0	Decrease in net assets of overseas subsidiaries on a JPY basis -16.0 Bn
Total accumulated other comprehensive income	-78.1	-93.4	-15.3	
Subscription rights to shares	3.5	3.8	0.3	
Minority interests	24.3	25.5	1.1	Ranbaxy +1.2 Bn
Total net assets	832.7	822.2	-10.5	
Total liabilities and net assets	1,518.5	1,495.0	-23.5	

10. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2011 Q2 Results	FY2012 Q2 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	62.0	45.2	-16.8	
Depreciation and amortization of goodwill	27.5	25.8	-1.7	
Increase/decrease in trade receivable and payable	-7.9	0.1	8.0	
Other, net	-17.0	3.6	20.6	
Income taxes paid	-18.7	-18.2	0.4	
Net cash provided by operating activities	46.0	56.5	10.5	
Cash flows from investing activities				
Net increase (decrease) in short-term investments	31.5	-70.4	-101.9	
(Acquisition of) proceeds from sales of non-current assets	-21.3	-40.7	-19.3	
Acquisition of investments in subsidiaries	-72.0	-0.0	72.0	FY2011: Plexikon Inc -72.0 Bn
Other, net	-23.0	9.1	32.0	FY2011: Kitasato Daiichi Sankyo Vaccine (KDSV) - Payment for transfer of business -16.1 Bn
Net cash used in investing activities	-84.8	-102.0	-17.3	
Cash flows from financing activities				
Net increase (decrease) in loans payable	7.7	-4.9	-12.6	
Redemption of bonds	-47.6	—	47.6	FY2011: Redemption of Ranbaxy's foreign currency convertible bond
Dividends paid	-21.7	-21.1	0.5	
Other, net	11.3	0.0	-11.3	FY2011: Investment in KDSV from The Kitasato Institute
Net cash used in financing activities	-50.3	-26.0	24.3	
Effect of exchange rate changes on cash and cash equivalents	-8.2	-3.4	4.8	
Net increase (decrease) in cash and cash equivalents	-97.3	-75.0	22.3	
Cash and cash equivalents, beginning of period	302.4	212.7	-89.7	
Cash and cash equivalents, at end of period	205.1	137.7	-67.4	

11. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
Daiichi Sankyo, Inc. (US)					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Daiichi Sankyo Europe GmbH					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

12. Major R&D Pipeline (Innovative pharmaceuticals)

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage		Remarks
Cardiovascular - Metabolics	DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF) Venous thromboembolism (VTE)	Global	P3	Study to be completed in FY2012
	CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome(ACS-PCI)	JP	P3	Application to be expected in FY2013
				Elective PCI	JP	P3	Applicaition to be expected in FY2013
				Ischemic Stroke	JP	P3	Study to be completed in FY2014
				Sickle cell disease	US	P2	
	CS-3150	-	MR antagonist	Hypertension	JP	P2	
	DS-7250	-	DGAT1 inhibitor	Diabetes Diabetes, Obesity	JP US/EU	P2 P1	
	DS-7309	-	Glucokinase activator	Diabetes	-	P1	
	DS-6930	-	Selective PPAR-gamma modulator	Diabetes	-	P1	
DS-8500	-	GPR119 agonist	Diabetes	-	P1		
DS-1442	-	CETP inhibitor	Dyslipidemia	-	P1		
Oncology	AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant Giant cell tumor	JP JP	P3 P2	
	ARQ 197	tivantinib	Met inhibitor	Hepatocellular cancer Colorectal cancer	US/EU US/EU	P2 P2	
	CS-1008	tigatuzumab	Anti-DR5 antibody	Hepatocellular cancer	Global	P2	
	DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P2	
				Non small cell lung cancer Esophageal cancer	JP JP	P2 P1	
	CS-7017	efatutazone	PPAR-gamma agonist	Non small cell lung cancer	US/EU	P2	
				Colorectal cancer	US/EU	P2	
				Non small cell lung cancer Colorectal cancer	Asia JP	P1 P1	
	U3-1287	-	Anti-HER3 antibody	Non small cell lung cancer Non small cell lung cancer	US/EU JP	P2 P1	
				Breast cancer Breast cancer	US JP	P2 P1	
	PLX4032	vemurafenib	BRAF inhibitor	Throid cancer	US/EU	P2	
	PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma	US	P2	
				Acute myeloid leukemia Glioblastoma Prostate Caner	US US US	P2 P2 P2	
	U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP	P1	
DS-2248	-	HSP90 inhibitor	Solid cancer	US	P1		
DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1		
ARQ 092	-	Akt inhibitor	Solid cancer	US	P1		
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1		
Others	AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Application	Application in Mar 2012
				Rheumatoid arthritis	JP	P2	
	CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic Anti-influenza	JP US/EU	P3 P1	Applicaition expected by the end of 2012
	DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
	DS-5565	-	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
	SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US	P2	
	DS-8587	-	Topoisomerase inhibitor	Anti-bacterial	-	P1	
	CS-4771	-	TLR4 inhibitor	Anti-sepsis	-	P1	
	PLX5622	-	FMS kinase inhibitor	Rheumatoid arthritis	-	P1	
	CS-0777	-	S1P receptor modulator	Immunomodulator	-	P1	
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	-	P1		
DS-7113	hydromorphone	opioid mu-receptor regulator	Narcotic analgesic	-	P1		

Change from announcement in July 2012

■ Change of stage

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Others	DD-723-B	perflubutane	Ultrasound contrast agent	Contrast enhanced ultrasonography for focal breast lesions	JP	Approved
Cardiovascular - Metabolics	CS-3150	-	MR antagonist	Hypertension	JP	P2
	DS-7250	-	DGAT1 inhibitor	Diabetes	JP	P2
	DS-8500	-	GPR119 agonism	Diabetes	-	P1
	DS-1442	-	CETP inhibitor	Dyslipidemia	-	P1

■ Discontinue

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Cardiovascular - Metabolics	CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome(ACS-MM)	Global	P3
	<Reason for discontinue> Superiority to clopidogrel did not confirm in the primary endpoint					
Oncology	ARQ 197	tivantinib	Met inhibitor	Non small cell lung cancer	Global	P3
	<Reason for discontinue> The interim analysis showed that the study would not meet its primary endpoint of improved overall survival.					
Others	DD-723-B	perflubutane	Ultrasound contrast agent	Contrast enhanced ultrasonography for prostate tumor	JP	P3
	<Reason for discontinue> Expected goal was not achieved.					

Cardiovascular-Metabolics

[Project after Phase 2]

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DU-176b	edoxaban	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP)
<ul style="list-style-type: none"> • An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates. • An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. • No severe hepatotoxicity signals in pre-clinical and clinical trials • Development by Daiichi Sankyo globally <ul style="list-style-type: none"> - A P3 multi-national trial in AF, completed its patient enrollment in Nov-2010. (ENGAGE AF-TIMI48) - A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism completed its patient enrollment in Oct-2012.(HOKUSAI VTE) • [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-747	prasugrel	Oral	Anti-platelet agent	Acute coronary syndrome (ACS-PCI) Elective PCI Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient(US, Asia) Efiient(EU)
<ul style="list-style-type: none"> • Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan • In August 2012, P3 trial (TRILOGY ACS) for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM) was obtained. The statistical superiority of prasugrel compared to clopidogrel was not confirmed. • A P2 study in pediatric sickle cell disease patients is on-going in US. • [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Efiient • [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient • [JP] P3 study for ACS-PCI patients (PRASFIT-ACS) has been completed. In addition, P3 studies for elective PCI and ischemic stroke are on-going. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-3150	-	Oral	MR antagonist	Hypertension	Exelixis	TBD
<ul style="list-style-type: none"> • P2 study with essential hypertension patients is ongoing. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-7250	-	Oral	DGAT1 inhibitor	Diabetes Obesity	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • P2 study with T2DM patients is ongoing. 						

Oncology

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ARQ 197	tivantinib	Oral	Met inhibitor	Hepatocellular cancer Colorectal cancer	ArQule	TBD
<ul style="list-style-type: none"> • Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. • Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. • A P3 clinical study for HCC is being planned. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	Hepatocellular cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5). • DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells. • Induces apoptosis of tumor cells expressing DR5 on the cell surface. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	CIMYM Biosciences	TBD
<ul style="list-style-type: none"> • A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). • Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-7017	efatutazone	Oral	PPAR-gamma agonist	Non small cell lung cancer Colorectal cancer	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • Inhibits growth of tumor cells in vitro without killing those cells. • Expected to be less toxic compared to standard chemotherapeutics. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
U3-1287	-	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<ul style="list-style-type: none"> •HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins. •HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX4032	vemurafenib	Oral	BRAF inhibitor	Thyroid cancer	Daiichi Sankyo (Plexikon)	Zelboraf
<ul style="list-style-type: none"> •Plexikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche •Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma Prostate Cancer	Daiichi Sankyo (Plexikon)	TBD
<ul style="list-style-type: none"> •Plexikon discovered PLX3397. •Clinical studies are on-going for several types of cancer. 						

Others

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
AMG 162	denosumab	Injection	Anti-RANKL antibody	Osteoporosis Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor	Amgen	SRE: Ranmark(JP) Osteoporosis: TBD
<ul style="list-style-type: none"> • Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. • July, 2007 In-licensed from Amgen • Application: Osteoporosis in Mar-2012 • P3 : Breast cancer adjuvant, P2: Rheumatoid arthritis, Giant cell tumor of bone • NDA approval: Skeletal Related Event(SRE) in Jan-2012 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, Treatment / Prophylactic	Daiichi Sankyo	Inavir(JP)
<ul style="list-style-type: none"> • Long-acting neuraminidase inhibitor • Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan • CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. • P3 for the flu prophylactic in Japan completed and NDA planned by the end of 2012 • [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DR-3355	levofloxacin	Injection	New quinolone	Anti-infection	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<ul style="list-style-type: none"> • As LCM, additional indications of urinary tract infection, surgical infection and gynecological infection, which are the biggest market next to respiratory tract infection are under development. • Ph3 comparative study for urinary tract infection and 4 open studies are on-going. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-5565	-	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • An $\alpha 2\delta$ ligand that binds to $\alpha 2\delta$ subunit of voltage-dependent Ca^{2+} channels • Considered to decrease excess Ca^{2+} influx to nerve terminals and to lower pain-related neurotransmitter release. • Clinical studies are on-going for diabetic peripheral neuropathic pain 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
SUN13837	-	Injection	Modulator of bFGF signaling system	Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> • Although SUN13837 acts upon the signal coupled with the FGF receptor and shows similar cell differentiation actions (nerve cell protection, nerve axon elongation) to bFGF, it does not show any cell multiplication function. • By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved • By making perceptual and motor-functional dysfunctions recovered at an early stage of postinjury, remnant functions in the chronic period are to be improved • Clinical studies are on-going for patients with severe spinal cord injury 						

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%
Ranbaxy Group																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-
Inter-segment Transactions																
Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

n

1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

2. Currency Rate (FY2010)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02

3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	201.6	+2.1%	100%	198.8	-4.0%	100%	213.7	-2.4%	100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%	12%	23.2	-11.6%	15%	31.1	-20.6%	1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
Ordinary Income	22%	43.4	+34.8%	12%	23.1	-12.6%	16%	33.7	-12.9%	0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
Net Income	11%	22.3	+122.8%	9%	18.3	+39.4%	12%	26.0	+30.0%	-4%	-7.8	-	7%	58.8	23.9	+68.6%
Ranbaxy Group																
Net sales	100%	54.9	+84.9%	100%	43.8	+20.1%	100%	35.5	-1.4%	100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%	15%	6.6	-1214.7%	2%	0.6	-60.0%	3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%	2%	0.9	-95.4%	16%	5.5	+374.9%	14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
Net Income	33%	18.4	-	10%	4.5	-68.3%	11%	3.8	-	-9%	-3.3	-	14%	23.3	19.1	+456.4%
Inter-segment Transactions																
Net sales		-0.1			-0.1			-0.1			-0.9			-1.2		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
Operating Income		-1.5			-0.7			-1.2			-1.9			-5.4		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
Ordinary Income		-1.5			-1.5			-1.3			-3.9			-8.2		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
Net Income		-7.6			-3.8			-2.2			1.6			-12.0		

4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	256.4	+12.9%	242.5	-0.4%	249.2	-2.3%	219.3	-3.2%	967.4	+1.6%
Japan Company (domestic sales)	105.3	+0.6%	103.0	-1.7%	116.8	-1.4%	91.0	+7.6%	416.0	+0.9%
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
Daiichi Sankyo Healthcare (OTC)	9.3	-2.7%	11.7	-12.9%	13.2	+9.1%	10.6	+23.2%	44.8	+2.6%
Daiichi Sankyo, Inc. (US)	33.6	+1.7%	33.9	+1.2%	34.6	+0.6%	28.4	-11.6%	130.5	-1.9%
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Luitpold Pharmaceuticals, Inc. (US)	14.7	+10.4%	13.7	+1.3%	11.5	-8.5%	14.0	+10.5%	53.9	+3.5%
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
Daiichi Sankyo Europe GmbH	14.8	-14.6%	16.6	-10.0%	18.1	-5.0%	16.9	-17.2%	66.4	-11.7%
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
Asia, South and Central America (ASCA)	5.9	+12.7%	7.1	+12.8%	6.8	+3.3%	7.6	-0.4%	27.4	+6.4%
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
Ranbaxy Laboratories Limited	54.8	+84.7%	43.7	+19.9%	35.4	-1.6%	38.0	-14.5%	171.9	+17.3%
Others	18.0	+25.6%	12.8	-25.1%	12.7	-20.2%	12.8	-20.0%	56.3	-11.1%
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

[Reference] Sales in Local Currency (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	365	+7.6%	394	+10.2%	422	+10.3%	342	-3.3%	1,522	+6.3%
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	160	+16.7%	159	+10.6%	142	+1.2%	168	+20.1%	629	+12.1%
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
Daiichi Sankyo Europe GmbH	126	-3.2%	149	+8.3%	161	+12.1%	150	-7.0%	587	+2.3%
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
Ranbaxy Laboratories Limited	28	+76.3%	21	+17.1%	19	+4.6%	21	-9.0%	89	+18.5%

5. Sales of Global Products (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	60.2	+7.6%	61.4	+3.4%	65.7	+1.6%	54.2	-7.0%	241.5	+1.4%
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
Levofloxacin	17.0	-14.3%	16.9	-28.0%	18.1	-18.3%	17.2	-21.1%	69.1	-20.7%
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
Pravastatin	11.9	-19.1%	11.8	-21.5%	11.6	-21.8%	9.6	-8.3%	44.9	-18.4%
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
Prasugrel (alliance revenue)	0.8	-	1.0	-	1.5	-	2.0	-	5.2	+889.6%
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

1. Summary of Consolidated Income Statement (FY2009)

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	227.1	+11.5%	100%	243.4	+20.2%	100%	255.1	+15.3%	100%	226.4	+5.6%	100%	952.1	110.0	+13.1%
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
Operating Income	12%	26.8	-33.1%	10%	24.1	+11.5%	15%	39.2	+7.6%	2%	5.4	-	10%	95.5	6.6	+7.5%
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
Ordinary Income	3%	7.2	-82.5%	19%	45.1	+140.0%	15%	38.4	+14.4%	6%	12.5	-	11%	103.1	47.9	+86.9%
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
Net Income	-3%	-6.4	-	10%	25.1	+182.7%	8%	20.6	-	1%	2.6	-96.8%	4%	41.9	257.4	-
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

2. Currency Rate (FY2009)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86	-7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16	-12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95	-0.05

3. Segment Information (FY2009)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	197.4	-3.1%	100%	207.0	+2.2%	100%	219.1	-1.0%	100%	181.9	+3.4%	100%	805.5	1.9	+0.2%
Cost of sales	23%	45.4	-6.7%	26%	54.3	+10.9%	25%	55.6	+4.6%	26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%	74%	152.7	-0.6%	75%	163.5	-2.8%	74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%	61%	126.5	-4.2%	57%	124.3	-1.5%	74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%	23%	46.7	+2.8%	21%	45.2	-3.5%	28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%	39%	79.8	-7.8%	36%	79.1	-0.3%	46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
Operating Income	15%	30.0	-24.9%	13%	26.2	+21.3%	18%	39.1	-6.7%	0%	-0.2	-	12%	95.2	-12.4	-11.5%
Non-operating income		2.9			2.0			1.8			0.4			7.1	-3.8	
Non-operating expenses		0.8			1.8			2.2			1.4			6.1	-13.9	
Ordinary Income	16%	32.2	-21.3%	13%	26.4	+40.5%	18%	38.7	-0.8%	-1%	-1.1	-	12%	96.1	-2.2	-2.3%
Extraordinary income		2.1			0.2			1.5			0.8			4.6	0.9	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%	13%	26.3	+54.4%	17%	37.7	+0.5%	-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6			13.1			17.7			-0.2			54.3	17.8	
Minority interests																
Net Income	5%	10.0	-60.1%	6%	13.2	+48.0%	9%	20.0	-27.9%	-5%	-8.3	-	4%	34.8	-15.1	-30.2%
Ranbaxy Group																
Net sales	100%	29.7		100%	36.4		100%	36.0		100%	44.5	+15.1%	100%	146.7	108.0	
Cost of sales	58%	17.1		56%	20.4		55%	19.8		41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6		44%	16.0		45%	16.2		59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4		46%	16.6		41%	14.6		43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1		6%	2.3		7%	2.4		8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3		39%	14.3		34%	12.2		36%	15.8	+5.6%	37%	54.6	39.6	
Operating Income	-6%	-1.8		-2%	-0.6		4%	1.6		16%	7.1	+1119.4%	4%	6.3	5.7	
Non-operating income		1.0			9.0			2.5			8.7			21.1	19.7	
Non-operating expenses		22.7			-11.9			2.9			0.7			14.5	-11.5	
Ordinary Income	-79%	-23.5		56%	20.2		3%	1.2		34%	15.1	-	9%	13.0	36.9	
Extraordinary income		0.0			0.0			0.0			1.3			1.3	1.2	
Extraordinary losses								0.0			0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5		56%	20.2		3%	1.1		37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6			6.0			1.3			9.2			9.8	17.7	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.1	
Net Income	-57%	-16.9		39%	14.2		-1%	-0.2		16%	7.1	-	3%	4.2	20.4	
Inter-segment Transactions																
Net sales																
Cost of sales																
Gross Profit																
SG&A expenses		1.5			1.5			1.5			1.5			6.0		
R&D expenses																
Other expenses		1.5			1.5			1.5			1.5			6.0		
Operating Income		-1.5			-1.5			-1.5			-1.5			-6.0		
Non-operating income																
Non-operating expenses																
Ordinary Income		-1.5			-1.5			-1.5			-1.5			-6.0		
Extraordinary income																
Extraordinary losses																
Income before income taxes and minority interests		-1.5			-1.5			-1.5			-1.5			-6.0		
Income taxes		7.0			-6.4			-3.0			-11.8			-14.1		
Minority interests		-8.9			7.1			0.7			6.5			5.3		
Net Income		0.5			-2.3			0.8			3.8			2.8		

4. Sales by Business Units (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	227.1	11.5%	243.4	20.2%	255.1	15.3%	226.4	5.6%	952.1	13.1%
Japan Company (domestic sales)	104.6	3.7%	104.8	5.3%	118.4	-1.4%	84.5	-1.9%	412.3	1.4%
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
Daiichi Sankyo Healthcare (OTC)	9.5	-6.9%	13.5	-2.1%	12.1	-8.2%	8.6	-14.1%	43.7	-7.4%
Daiichi Sankyo, Inc. (US)	33.0	-11.2%	33.5	5.6%	34.4	5.8%	32.1	15.2%	133.0	2.9%
Olmесartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Luitpold Pharmaceuticals, Inc. (US)	13.4	-1.1%	13.5	-0.4%	12.6	-6.4%	12.7	18.9%	52.1	1.9%
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
Daiichi Sankyo Europe GmbH	17.3	14.1%	18.4	-0.4%	19.1	6.1%	20.4	9.7%	75.2	7.1%
Olmесartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Asia, South and Central America (ASCA)	5.3	0.5%	6.3	7.1%	6.6	11.7%	7.7	27.5%	25.8	12.1%
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
Ranbaxy Laboratories Limited	29.7	-	36.4	-	36.0	-	44.4	14.9%	146.6	-
Others	14.4	-33.2%	17.1	-13.6%	15.9	-12.3%	16.0	-3.0%	63.4	-16.5%
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Efient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

[Reference] Sales in Local Currency (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	339	-4.6%	357	21.7%	382	13.4%	354	18.0%	1,433	11.4%
Olmесartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	137	6.2%	144	14.5%	140	1.1%	140	21.4%	561	10.3%
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
Daiichi Sankyo Europe GmbH	131	40.6%	138	20.8%	144	5.9%	161	9.8%	574	17.1%
Olmесartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmotec/Olmotec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
Ranbaxy Laboratories Limited	16	-	18	-	18	-	23	17.9%	75	-

5. Sales of Global Products (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmесartan	56.0	10.5%	59.4	10.2%	64.7	12.3%	58.3	19.0%	238.3	12.9%
Olmotec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmotec/Olmotec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
Levofloxacin	19.8	-23.2%	23.5	-0.3%	22.1	-14.2%	21.8	-3.5%	87.2	-10.7%
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
Pravastatin	14.7	-8.5%	15.0	-5.2%	14.8	-10.8%	10.5	-14.9%	55.0	-9.6%
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
Prasugrel (alliance revenue)	0.0	-	1.0	-	0.3	-	-0.7	-	0.5	-
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Efient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-